Muscle MRI of classic infantile pompe patients: Fatty substitution and edema‐like changes
ABSTRACT Introduction The aim of this study was to evaluate the muscle MRI pattern of 9 patients (median age: 6.5 ± 2.74 years) affected by classic infantile‐onset Pompe disease who were treated with enzyme replacement therapy. Methods We performed and qualitatively scored T1‐weighted (T1‐w) sequenc...
Saved in:
Published in | Muscle & nerve Vol. 55; no. 6; pp. 841 - 848 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.06.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | ABSTRACT
Introduction
The aim of this study was to evaluate the muscle MRI pattern of 9 patients (median age: 6.5 ± 2.74 years) affected by classic infantile‐onset Pompe disease who were treated with enzyme replacement therapy.
Methods
We performed and qualitatively scored T1‐weighted (T1‐w) sequences of the facial, shoulder girdle, paravertebral, and lower limb muscles and short‐tau inversion recovery (STIR) sequences of the lower limbs using the Mercuri and Morrow scales, respectively.
Results
On T1‐w images, mild (grade 1) or moderate (grade 2) involvement was found in the tongue in 6 of 6 patients and in the adductor magnus muscle in 6 of 9. STIR hyperintensity was detected in all areas examined and was categorized as limited to mild in 5 of 8 patients.
Conclusions
On T1‐w sequences, mild/moderate adipose substitution in the adductor magnus and tongue muscles was documented. STIR edema‐like alterations of thigh and calf muscles are novel findings. Correlations with biopsy findings and clinical parameters are needed to fully understand these findings. Muscle Nerve 55: 841–848, 2017 |
---|---|
Bibliography: | None of the other authors have anything to disclose. Conflicts of Interest Funding Dr. Pichiecchio received a speaker fee from Genzyme. Dr. Parini received travel and research grants and honoraria for speaking engagements from Shire, Genzyme, BioMarin, and SOBI. Dr. Fecarotta received travel support for meeting attendance from Actelion Pharmaceuticals Ltd and Genzyme, a Sanofi Company. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0148-639X 1097-4598 |
DOI: | 10.1002/mus.25417 |